Myfortic

ApprovedSmall molecule

Novartis

Myfortic is one of 186 small molecule programs targeting Ischemia Reperfusion Injury. It is currently in Approved.

Indications

Total Trials

Active Trials

185

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemia Reperfusion InjuryActive, not recruiting

Intermediate UveitisActive, not recruiting

Liver TransplantActive, not recruiting

Kidney TransplantActive, not recruiting

FibrosisActive, not recruiting

Lupus NephritisActive, not recruiting

UveitisActive, not recruiting

Ischemia Reperfusion InjuryApproved

Active, not recruiting

Intermediate UveitisPhase 3

Active, not recruiting

Liver TransplantPreclinical

Active, not recruiting

Kidney TransplantApproved

Active, not recruiting

FibrosisPhase 3

Active, not recruiting

Lupus NephritisPreclinical

Active, not recruiting

UveitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Myfortic

Novartis

Approved

3 2

Nulojix

Bristol-Myers Squibb

Preclinical

16 3

Simulect

Novartis

Preclinical

15 4

Medrol

Pfizer

Preclinical

12 5

Zinbryta

Roche

Preclinical

6 6

Cysteine Hydrochloride

Novartis

Preclinical

1 7

Sensipar

Amgen

Preclinical

1 8

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 10

Jardiance

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ARecruiting

Transplant Recipient

NCT01999361

Clinical

Trials by Indication[1]

Liver Transplant6 trials

A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients

Completed· Astellas logo

Astellas·Phase 4·NCT01018914·44 enrolled

Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients

Completed·UUniversity of Pittsburgh·N/A·NCT00336895·29 enrolled

Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

Enrolling by invitation·—·Phase 4·NCT02081755·336 enrolled

Show 3 more trials

A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients

Completed·UUniversity of Pittsburgh·N/A·NCT00336817·30 enrolled

Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation

Unknown status·AArmin Goralczyk·Phase 2·NCT00890253·29 enrolled

Enteric Coated Myfortic for Liver Transplant Recipients

Withdrawn·TThe University of Texas Health Science Center, Houston·Phase 4·NCT00167492

Kidney Transplant3 trials

Freedom Study: Myfortic in Kidney Transplant Patients

Completed· Novartis logo

Novartis·Phase 3·NCT00101738·342 enrolled

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

Withdrawn·UUniversity of Wisconsin, Madison·Phase 4·NCT02130817

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Completed· Novartis logo

Novartis·Phase 3·NCT00514514·802 enrolled

Renal Transplant2 trials

Desensitization of Renal Transplant Candidates

Completed·UUniversity of Florida·Phase 1·NCT00298883·9 enrolled

Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)

Unknown status·—·Phase 4·NCT00676221·110 enrolled

Intermediate Uveitis1 trial

Myfortic for the Treatment of Non-infectious Intermediate Uveitis

Completed·SSTZ eyetrial·Phase 3·NCT01092533·44 enrolled

Heart Transplant1 trial

Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms

Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 3·NCT00468936·100 enrolled

10 more indications

Cardiovascular1 trial

Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring

Withdrawn·UUniversity of Saskatchewan·Phase 4·NCT02058875

Uveitis1 trial

Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study

Unknown status·GGenovate Biotechnology Co., Ltd.,··NCT01261169·40 enrolled

Renal Transplant Recipients1 trial

Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)

Completed· Novartis logo

Novartis·Phase 2·NCT01596062·16 enrolled

Ischemia Reperfusion Injury1 trial

Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation

Withdrawn·GGeorgetown University·Phase 4·NCT01149993

Fibrosis1 trial

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

Completed· Novartis logo

Novartis·Phase 3·NCT01079143·194 enrolled

Treatment1 trial

Myfortic - Treatment for Extensive cGvHD

Terminated·EEuropean Society for Blood and Marrow Transplantation·Phase 3·NCT00298324·34 enrolled

Transplant Recipient1 trial

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Recruiting·RRodolfo Alejandro·N/A·NCT01999361·18 enrolled

Tacrolimus1 trial

Pharmacokinetic Profile of Myfortic in Combination With Tacrolimus in Fed Versus Fasting State

Completed·UUniversity of Utah·Phase 4·NCT00585468·21 enrolled

Endoscopy1 trial

Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®

Completed·UUniversity of California, Los Angeles·Phase 4·NCT00652834·23 enrolled

Lupus Nephritis1 trial

Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population

Completed· Novartis logo

Novartis··NCT04645589·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for Myfortic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Myfortic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Myfortic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Myfortic

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Liver Transplant6 trials

Kidney Transplant3 trials

Renal Transplant2 trials

Intermediate Uveitis1 trial

Heart Transplant1 trial

Cardiovascular1 trial

Uveitis1 trial

Renal Transplant Recipients1 trial

Ischemia Reperfusion Injury1 trial

Fibrosis1 trial

Treatment1 trial

Transplant Recipient1 trial

Tacrolimus1 trial

Endoscopy1 trial

Lupus Nephritis1 trial

References

Drug Info

Quick Facts

Related News